Autolus Therapeutics plc American Depositary Receipt
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Autolus Therapeutics plc American Depositary Receipt represents shares in Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in next-generation, programmed T cell therapies. The company develops autologous CAR T cell therapies using proprietary modular programming technologies that engineer precisely targeted, controlled, and highly active T cells to recognize cancer cells, overcome their defense mechanisms, and eliminate them. Its pipeline targets hematological malignancies such as adult and pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma, as well as solid tumors and autoimmune diseases. Autolus Therapeutics employs advanced chimeric antigen receptors combining antibody tumor recognition with T cell activation domains, alongside proprietary viral vector and semi-automated manufacturing processes for patient-specific therapies. Focused on oncology, immunology, and rare diseases, the company advances clinical-stage programs through pivotal trials and regulatory submissions, positioning it as a key player in innovative cell therapy development. Founded in 2014 and headquartered in London, United Kingdom, Autolus Therapeutics collaborates with academic institutions and industry partners to deliver potential life-changing treatments.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Christian Martin Itin Ph.D.
- Employees
- 647
- Headquarters
- London, United Kingdom
- Website
- www.autolus.com